Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

ORIC Pharmaceuticals is supported by two differentiated clinical assets that de-risk the story: rinzimetostat in post-abiraterone mCRPC and enozertinib in atypical EGFR NSCLC, both showing efficacy signals that compare favorably with current standards while emphasizing better tolerability and CNS activity. Rinzimetostat’s clean phase 1b profile—84% 5-month landmark rPFS, 6% grade 3 TRAEs, zero dose reductions, and no SPMs to date—strengthens the case that its EED-targeting approach can compete with Pfizer’s mevrometostat on safety and dosing convenience. Enozertinib adds further upside with a 60% cORR in 1L ex20ins and 80% ORR in 1L PACC, while the company ended 2Q26 with roughly $387.6M in cash and runway into 2H28, supporting execution through upcoming catalysts.

ORIC Pharmaceuticals is facing a weak fundamental setup because its lead oncology programs still rest on small, uncontrolled early-stage datasets, with rinzimetostat supported by only 18 evaluable patients and about 4.9 months of median follow-up, leaving efficacy and durability unproven. The competitive bar is also high: Pfizer’s mevrometostat already has randomized phase 1 data, three concurrent phase 3 trials, and a likely NDA timeline over a year ahead, while ORIC’s own safety edge may erode as patient exposure expands. On top of that, the FDA’s view that PRC2 inhibition carries a class-wide malignancy risk creates a major regulatory overhang, and if negative signals emerge, the stock could reprice sharply despite the company’s broader pipeline.